| Compound | Humanin |
|---|---|
| Category | Mitochondrial-derived peptide |
| Class | Metabolic and Mitochondrial Compounds |
| Evidence tier | Preclinical |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
This entry covers Humanin, a mitochondrial-derived peptide, graded "Preclinical" in this catalog's evidence system. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
A mitochondrially encoded peptide studied for cytoprotective and neuroprotective effects in laboratory models of aging.
Mechanism of Action
Humanin binds receptor complexes including FPRL1 and the IGFBP-3 receptor family in vitro, activating cytoprotective signaling.
Research and Evidence
Preclinical models of neurodegeneration and ischemia report benefit; human data are limited to observational correlative studies.
Safety and Side Effects
No human administration safety data.
Frequently Asked Questions
What is the evidence tier of Humanin?
Humanin is graded "Preclinical" on this site. The evidence base for this compound is dominated by animal and cell-culture studies. Mechanism may be plausible; human benefit and safety are unestablished.
Is Humanin an approved medicine?
No. Preclinical means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Humanin?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for humanin studies (none registered as interventions). [source]
Evidence tier: Preclinical · Last reviewed: 2026-09-05 · Sources cited below.